Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press12210.17650/2220-3478-2015-1-26-36REVIEWОБЗОРЫ ЛИТЕРАТУРЫSTUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCERДАННЫЕ ИССЛЕДОВАНИЙ ПРИ КRAS- И RAS-НЕМУТИРОВАННОМ (ДИКОМ) ТИПЕ КОЛОРЕКТАЛЬНОГО РАКАGorbunovaV. A.ГорбуноваВ. А.
Russian Federation

N.N. Blokhin Russian Cancer Research Center; 24 Kashirskoye Shosse, Moscow, 115478, Russia

ФГБНУ «РОНЦ им. Н.Н. Блохина»; Россия, 115 478, Москва, Каширское шоссе, 24

 

veragorbounova@mail.ruN.N. Blokhin Russian Cancer Research CenterФГБНУ «РОНЦ им. Н.Н. Блохина»260520155126362605201526052015Copyright ©; 2015, ABV-pressCopyright ©; 2015, АБВ-пресс2015ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/122

 Analysis of latest trials, comparing treatment schemes including chemotherapy with anti-EGFR monoclonal antibodies or bevacizumab is presented in this article. The data in these trials is inconsistent, but detailed analysis of FIRE-3 trial allows to distinguish a wild-type RAS patient group that benefits most from chemotherapy with cetuximab or panitumumab as 1st line metastatic colorectal cancer treatment. A final analysis of this patient group in CALGB/SWOG 80 405 trial is pending. The RAS analysis is pivotal for choice of 1st line chemotherapy.

В статье приводится анализ последних исследований, сравнивающих режимы лекарственной терапии, включающих антиEGFR моноклональные антитела,  с теми же режимами химиотерапии (ХТ)  с бевацизумабом. Данные этих исследований неоднозначны, однако обстоятельный анализ исследования FIRE-3 позволяет выделить подгруппы пациентов с предпочти- тельным назначением в качестве 1-й линии лечения метастатического колоректального рака с отсутствием мутации гена RAS (RAS дикого типа) схем ХТ в сочетании с цетуксимабом либо панитумумабом. Ожидается окончательный анализ данной категории пациентов в исследовании CALGB/SWOG 80 405. Обязательным является исследование опухолей на мутацию RAS для выбора 1-й линии.

colorectal cancermonoclonal antibodiescetuximabpanitumumabantiangiogenic drug bevacizumabchemotherapyколоректальный ракмоноклональные антителацетуксимабпанитумумабантиангиогенный препарат бевацизумабхимиотерапия1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в Рос- сии и странах СНГ в 2012 г. Вестник РОНЦ им. Н.Н. Блохина РАМН 2014. [Davydov M.I., Aksel E.M. Statistics of malignant neoplasms in Russia and the CIS countries in 2012. Vestnik RONC im. N.N. Blokhina = Bulletin of N.N. Blokhin Russian Cancer Research Center 2014 (In Russ.)].Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в Рос- сии и странах СНГ в 2012 г. Вестник РОНЦ им. Н.Н. Блохина РАМН 2014. [Davydov M.I., Aksel E.M. Statistics of malignant neoplasms in Russia and the CIS countries in 2012. Vestnik RONC im. N.N. Blokhina = Bulletin of N.N. Blokhin Russian Cancer Research Center 2014 (In Russ.)].2. Treatment of colorectal cancer. Eds: Baxter N.N., Burnstein M.J. Clinical Review Articles. Surg Oncol Clin N Am 2014 Jan;23(1).Treatment of colorectal cancer. Eds: Baxter N.N., Burnstein M.J. Clinical Review Articles. Surg Oncol Clin N Am 2014 Jan;23(1).3. Stintzing S., Jung A., Rossius L. et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Presented at: European Cancer Congress 2013; Sept 27 – Oct 1, 2013; Amsterdam. Abstract LBA17.Stintzing S., Jung A., Rossius L. et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Presented at: European Cancer Congress 2013; Sept 27 – Oct 1, 2013; Amsterdam. Abstract LBA17.4. Ciardiello F., Lenz H.J., Kohne C.H. et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J Clin Oncol 2014;32(5s) suppl; Abstr 3506.Ciardiello F., Lenz H.J., Kohne C.H. et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J Clin Oncol 2014;32(5s) suppl; Abstr 3506.5. Tejpar S., Lenz H.J., Köhne C.H. et al. Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study. J Clin Oncol 2014;32(Suppl 3) Abstr LBA444.Tejpar S., Lenz H.J., Köhne C.H. et al. Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study. J Clin Oncol 2014;32(Suppl 3) Abstr LBA444.6. Oliner K.S., Douillard J.-Y., Siena S. et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). J Clin Oncol 2013;31(suppl; abstr 3511).Oliner K.S., Douillard J.-Y., Siena S. et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). J Clin Oncol 2013;31(suppl; abstr 3511).7. Schwartzberg L.S., Rivera F., Karthaus M. et al. Analysis of KRAS/NRAS mutations in PEAK: a randomized study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). J Clin Oncol 2013;31(suppl; abstr 3631).Schwartzberg L.S., Rivera F., Karthaus M. et al. Analysis of KRAS/NRAS mutations in PEAK: a randomized study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). J Clin Oncol 2013;31(suppl; abstr 3631).8. Heinemann V., von Weikersthal L.F., Decker T. et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). 2013 ASCO Annual Meeting. Abstract LBA3506. Presented June 1, 2013.Heinemann V., von Weikersthal L.F., Decker T. et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). 2013 ASCO Annual Meeting. Abstract LBA3506. Presented June 1, 2013.9. Naughton M.J., Schrag D., Venook A.P. et al. Quality of life (QOL) and toxicity among patients in CALGB 80405. Proc Am Soc Clin Oncol 2013;31(abstr 3611).Naughton M.J., Schrag D., Venook A.P. et al. Quality of life (QOL) and toxicity among patients in CALGB 80405. Proc Am Soc Clin Oncol 2013;31(abstr 3611).10. Schwartzberg L.S., Rivera F., Karthaus M. et al. PEAK (study 20070509): a randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild-type (WT) KRAS metastatic colorectal cancer (mCRC). J Clin Oncol 2012;30(suppl 34; abstr 446).Schwartzberg L.S., Rivera F., Karthaus M. et al. PEAK (study 20070509): a randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild-type (WT) KRAS metastatic colorectal cancer (mCRC). J Clin Oncol 2012;30(suppl 34; abstr 446).11. Venook A.P., Niedzwiecki D., Lenz H.J. et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI)Venook A.P., Niedzwiecki D., Lenz H.J. et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI)or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2014;32:5s (suppl; abstr LBA3).12. Saltz L.B., Clarke S., Diaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin- based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013–9.Saltz L.B., Clarke S., Diaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin- based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013–9.13. Yamakazi K., Nagase M., Tamagawa H. et al. A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G) (abstract). J Clin Oncol 2014;32:5s(suppl; abstr 3534).Yamakazi K., Nagase M., Tamagawa H. et al. A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G) (abstract). J Clin Oncol 2014;32:5s(suppl; abstr 3534).14. Stintzing S., Fischer von Weikersthal L., Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer – subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol 2012;23:1693–9.Stintzing S., Fischer von Weikersthal L., Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer – subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol 2012;23:1693–9.15. Heinemann V., von Weikersthal L.F., Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065.Heinemann V., von Weikersthal L.F., Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065.16. Stintzing S., Modest D.P., Fischer von Weikersthal L. et al. Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306). A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. ASCO GI 2015, poster 515, Abstract 140067.Stintzing S., Modest D.P., Fischer von Weikersthal L. et al. Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306). A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. ASCO GI 2015, poster 515, Abstract 140067.17. Schwartzberg L.S., Rivera F., Karthaus M. et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014;32:2240–7.Schwartzberg L.S., Rivera F., Karthaus M. et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014;32:2240–7.18. Cheng A., Cornelio G., Price T. et al. Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC). J Clin Oncol 2015; 33(suppl 3; abstr 566).Cheng A., Cornelio G., Price T. et al. Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC). J Clin Oncol 2015; 33(suppl 3; abstr 566).19. Modest D.P., Stintzing S., Fischer von Weikersthal L., Decker T. et al. Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial. J Clin Oncol 2014;32:5s (suppl; abstr 3558^).Modest D.P., Stintzing S., Fischer von Weikersthal L., Decker T. et al. Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial. J Clin Oncol 2014;32:5s (suppl; abstr 3558^).20. Heinemann V., Modest D.P., Fischer von Weikersthal L. et al. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol 2014;32:5s (suppl); abstr 3600.Heinemann V., Modest D.P., Fischer von Weikersthal L. et al. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol 2014;32:5s (suppl); abstr 3600.